FGF2 (Fibroblast Growth Factor 2 / Basic FGF / bFGF)

FGF2 — fibroblast growth factor 2, historically called basic fibroblast growth factor (bFGF) — is a pleiotropic paracrine growth factor and canonical activator of satellite cells (muscle stem cells). Its most aging-relevant role is as an age-elevated niche signal that chronically disrupts satellite cell quiescence, driving stem cell pool depletion in aged skeletal muscle and contributing to stem-cell-exhaustion-driven sarcopenia ¹. Beyond muscle, FGF2 participates in angiogenesis, tissue repair, wound healing, fibrosis, and is a component of the senescence-associated secretory phenotype (SASP) — making it a pleiotropic actor across multiple aging hallmarks.

Identity

UniProt: P09038 (FGF2_HUMAN) — reviewed Swiss-Prot entry; accessed 2026-06-15
NCBI Gene: 2247
HGNC symbol: FGF2 (alias: FGFB)
Ensembl: ENSG00000138685
Mouse ortholog: Fgf2 (one-to-one ortholog; gene function is highly conserved between mouse and human)
Protein length: 288 amino acids (canonical isoform); molecular weight 30,770 Da
Family: FGF family, paracrine subfamily (FGF1–10); beta-trefoil fold

Isoforms

FGF2 is unusual among growth factors in generating multiple protein isoforms from a single mRNA via alternative translation initiation ². Two functional classes operate in distinct cellular compartments with distinct roles:

Isoform class	Molecular weight	Initiation codon	Localization	Primary role
Low-molecular-weight (LMW)	18 kDa	AUG (canonical)	Secreted to extracellular matrix; cytoplasmic	Paracrine growth factor; FGFR binding; heparin/HSPG-dependent
High-molecular-weight (HMW)	22, 22.5, 24, 34 kDa	Non-AUG (CUG) upstream	Predominantly nuclear	Intracrine/nuclear signaling; DNA damage response; proliferation-independent functions

The 18 kDa LMW isoform is the classical secreted form that acts on FGF receptors. The HMW nuclear isoforms accumulate in stressed or senescent cells and have been implicated in nuclear FGF signaling distinct from FGFR activation ².

Unconventional secretion. The 18 kDa LMW FGF2 lacks a classical signal peptide and is exported by an ER/Golgi-independent, phosphoinositide-regulated mechanism involving heparan sulfate proteoglycans (HSPGs) at the cell surface. Phosphorylation at Tyr-215 regulates this unconventional secretion route ².

Signaling mechanism

FGF2 signals primarily through four receptor tyrosine kinase receptors (FGFR1–4) on target cells. A key feature is obligate dependence on heparan sulfate proteoglycans (HSPGs) as co-receptors:

FGF2 binds to HSPGs (particularly syndecan-4 and perlecan) in the extracellular matrix
HSPG-bound FGF2 is presented to and stabilizes the FGF2:FGFR complex at the cell surface
FGFR dimerization → transautophosphorylation of intracellular kinase domains
Recruitment of docking proteins (FRS2α/β) → downstream branching:
- RAS–MAPK (ERK1/2) cascade — proliferation, differentiation
- PI3K–AKT pathway — survival, cell growth
- PLCγ (phospholipase Cγ) pathway — calcium mobilization, PKC activation

The HSPG co-receptor dependence means that changes in heparan sulfate composition of the muscle niche with aging directly modulate FGF2 signaling availability. In aged muscle, altered HSPG structure changes the balance between FGF2 retention vs. availability and modulates how FGF2 signals to satellite cells ³.

SPROUTY1 (SPRY1) — a cytoplasmic inhibitor of RAS/MAPK signaling — is a critical negative regulator of FGF2 in satellite cells: SPRY1 expression in quiescent satellite cells counteracts FGF2-driven quiescence exit and thus maintains the stem cell pool in the face of chronic niche FGF2 elevation. In the aged muscle, quiescence-retaining (label-retaining cell / LRC) satellite cells retain high Spry1 expression, while cycling non-LRC satellite cells show reduced Spry1 and are more sensitive to FGF2-driven quiescence loss ¹.

Role in aging: the satellite cell / muscle-niche axis

This is FGF2’s most mechanistically worked-out aging-specific role and the primary motivation for this page.

The Chakkalakal 2012 discovery

Chakkalakal et al. published in Nature in 2012 the landmark finding that elevated FGF2 in the aged muscle niche is a primary driver of satellite cell quiescence loss and stem pool depletion ¹:

In aged mouse muscle under homeostatic (non-injured) conditions, myofibers express FGF2 at levels that drive satellite cells to exit quiescence and undergo abortive activation — cells that activate but fail to self-renew and are lost from the pool.
SPRY1 as a protective quiescence guardian: Among the quiescent satellite cell subpopulation in aged muscle, Spry1 expression is selectively enriched in the slow-dividing, quiescence-retaining (label-retaining cell / LRC) fraction. Spry1 is decreased by Fgf2 signaling; quiescent LRC cells express high Spry1 precisely because they are not yet driven to cycle by the FGF2 niche signal. This is not a global “upregulation” in aged satellite cells — rather, Spry1 is a marker and mediator of quiescence that is differentially preserved in the cells that best resist the aged niche.
Loss-of-Spry1 experiment: Genetic removal of Spry1 from satellite cells (Pax7-CreER^TM^ × Spry1^fl/fl^) in aged mice increased FGF signaling, accelerated quiescence exit, and produced more severe satellite cell depletion (~50% reduction vs aged controls after long-term deletion). This confirmed that Spry1 is functionally required to maintain quiescence against the aged FGF2 niche signal.
Therapeutic rescue via two distinct endpoints: (1) FGFR1 inhibition with SU5402 (delivered in vivo via implanted anion-exchange resin beads, 6-week experiment) prevented quiescence loss — the BrdU+ cycling fraction in aged muscle was normalized to adult-control levels, and elevated apoptosis in aged satellite cells was attenuated; SU5402 was not tested for pool depletion in this experimental window. (2) Spry1 overexpression (Spry1OX) in satellite cells (5-month induction) prevented pool depletion: satellite cell number per fibre was twofold higher in aged Spry1OX mice vs aged controls. The two rescue arms tested different endpoints at different timescales; it is the Spry1OX arm (not SU5402) that directly demonstrated pool-depletion prevention.
Study design: In vivo mouse model (adult ~4–8 months vs. aged ~22–24 months); genetic manipulation of FGF pathway components in satellite cells via Pax7-CreER^TM

Dimension	Status
Pathway conserved in humans?	yes — FGF2/FGFR1/SPRY1 axis is conserved; FGF2 is expressed in human satellite cell niche
Phenotype conserved in humans?	partial — satellite cell pool decline with age is documented in humans; whether FGF2 niche elevation is the causal driver has not been directly tested
Replicated in humans?	no — genetic/mechanistic evidence is murine; human correlative data only

gap/needs-human-replication — Direct evidence that aged-niche FGF2 elevation depletes the human satellite cell pool is not established. The Li 2024 epigenome-wide association study biomarker data (blood FGF2_30 hypomethylation correlates with sarcopenia severity) is consistent with this model but is associational, not mechanistic.

Heparan sulfate as aging mediator of the FGF2/satellite-cell axis

In muscle, the composition of heparan sulfate chains on HSPGs changes with aging and differentiation state. Ghadiali et al. 2017 showed that dynamic changes in HSPG heparan sulfate sulfation patterns during muscle aging alter both myoblast fate decisions and FGF2 signaling availability — the extracellular matrix changes of aging thus feed into the FGF2 niche signal ³. This positions heparan sulfate remodeling as a mechanistic link between aged extracellular matrix and aberrant FGF2 paracrine signaling to satellite cells.

Exercise as a modifier

Resistance exercise in aged mice reduced FGF2 expression in skeletal muscle ⁴, suggesting that exercise may partially normalize the aged FGF2 niche environment. This finding is in a small animal study and has not been directly replicated in human muscle biopsies with concurrent satellite cell pool measurements. gap/needs-human-replication

FGF2 as a SASP component

FGF2 is a well-documented component of the senescence-associated secretory phenotype (SASP) — the pro-inflammatory secretome released by senescent cells ⁵. Senescent fibroblasts and other mesenchymal cells secrete FGF2 alongside canonical SASP cytokines (interleukin-6 / IL-6, interleukin-8 / IL-8, matrix metalloproteinases / MMPs). In the context of muscle aging:

Accumulation of senescent cells in the muscle interstitium with age (see cellular-senescence) contributes to local FGF2 elevation via SASP secretion — independent of myofiber expression.
SASP-derived FGF2, combined with myofiber-expressed FGF2, compounds the niche signal experienced by satellite cells.
This creates a potential positive feedback loop: FGF2-driven satellite cell depletion → reduced regenerative capacity → accumulation of dysfunctional cells → more senescent SASP producers → more FGF2.

The SASP component also connects FGF2 to the altered-intercellular-communication hallmark via paracrine spread of senescence signals.

Other aging-relevant roles

Angiogenesis

FGF2 is one of the canonical pro-angiogenic growth factors, acting via FGFR1 on endothelial cells to promote proliferation, migration, and tube formation. In aging, the angiogenic response to ischemia is blunted, partly through reduced growth factor responsiveness — though the role of FGF2 specifically in aging-associated vascular rarefaction is complex and not fully resolved. gap/no-mechanism — causal contribution of FGF2 to age-related capillary rarefaction in human muscle has not been established.

Wound healing and fibrosis

FGF2 is released at wound sites and participates in granulation tissue formation, re-epithelialization, and angiogenesis during tissue repair. With aging, wound healing is impaired; changes in FGF2 levels and receptor responsiveness contribute. However, chronically elevated FGF2 (as in fibrotic contexts) can paradoxically drive fibrosis over repair — particularly when combined with elevated TGF-β signaling that predominates in aged tissue. In muscle, this is consistent with the fibroadipogenic progenitor (FAP) fate-shift toward collagen-secreting fibrogenic cells observed in aged muscle (see skeletal-muscle).

FGF2 and inflammation

FGF2 can activate NF-κB signaling through FGFR-independent pathways and may contribute to the chronic low-grade inflammatory state of aged tissue (chronic-inflammation). FGF2 also synergizes with other SASP cytokines to maintain autocrine inflammatory loops in senescent cells.

Hallmark connections

Hallmark	FGF2 mechanism
stem-cell-exhaustion	Primary role — chronic FGF2 from aged muscle niche drives satellite cell quiescence loss and pool depletion ¹; SPRY1 expression in quiescent satellite cells is the key counterregulatory defense; loss of Spry1 worsens depletion
altered-intercellular-communication	FGF2 as paracrine niche signal from myofibers → satellite cells; SASP-secreted FGF2 from senescent interstitial cells creates aberrant intercellular crosstalk
chronic-inflammation	SASP FGF2 component; NF-κB crosstalk; fibrotic/inflammatory niche remodeling
cellular-senescence	FGF2 is a SASP secretory product of senescent cells; HMW nuclear FGF2 isoforms may participate in senescence responses

Pathway membership

fgf-signaling — canonical FGF ligand of the paracrine subfamily (FGF1–10); acts via FGFR1 primarily in muscle/stem cell contexts; distinct from endocrine FGF21/FGF23 axis; see fgf-signaling for pathway-level aging pharmacology
ras-mapk — primary downstream effector cascade (ERK1/2); drives proliferation and differentiation
pi3k-akt-pathway — secondary downstream effector; survival and growth signaling

Pharmacology and druggability

druggability-tier: null — No clinically validated drug targets FGF2 for an aging indication. gap/no-opentargets-entry

Clinical-stage FGFR inhibitors exist (erdafitinib, pemigatinib, infigratinib — FDA-approved for oncology, targeting FGFR fusions/mutations in bladder cancer, cholangiocarcinoma). These pan-FGFR or selective inhibitors would broadly suppress FGF2/FGFR1 signaling but carry significant on-target toxicity (hyperphosphatemia via FGF23/FGFR4 axis, bone effects) that makes chronic use in aging untenable without substantial selectivity advances.

Potential strategies based on Chakkalakal 2012:

FGFR1-selective inhibition in aged muscle — preclinical proof-of-concept only; no aging-directed clinical trial
SPRY1 gene therapy / small-molecule SPRY1 induction — conceptually attractive but no validated approach
HSPG modification — altering heparan sulfate composition to reduce FGF2 sequestration / presentation; highly speculative

No aging-specific clinical trial is registered targeting the FGF2/satellite-cell axis as of 2026-06-15. gap/needs-human-replication

Limitations and gaps

Human mechanistic evidence gap. The satellite-cell niche FGF2 depletion mechanism is established in mice (Chakkalakal 2012). Human muscle biopsies confirm satellite cell decline with age and FGF2 expression in muscle, but a controlled mechanistic experiment (FGFR inhibition restoring human satellite cell quiescence) has not been performed. gap/needs-human-replication
No MR causal evidence. Mendelian randomization using genetic instruments for circulating FGF2 levels has not been applied to muscle outcomes or aging phenotypes as of the literature search date. mr-causal-evidence: not-tested. gap/needs-replication
SPRY1 expression in human aging. Whether the LRC/non-LRC Spry1 differential seen in aged mouse satellite cells (high Spry1 in quiescent LRCs, low in cycling non-LRCs) is conserved in human satellite cells is not established at single-cell resolution. gap/needs-human-replication
GTEx aging correlation not queried. Tissue-specific expression changes of FGF2 with aging across GTEx tissues would inform which tissues bear the highest FGF2-driven aging burden. gtex-aging-correlation: null. gap/needs-tissue-expression-data
FGF2 isoform-specific roles in aging. Whether HMW vs. LMW FGF2 isoforms contribute differentially to aging phenotypes is not well characterized. gap/no-mechanism
Contradictory FGF2 biology in muscle. FGF2 knockout studies in aged mice have produced complex phenotypes — some data suggest baseline FGF2 is required for satellite cell maintenance, indicating that the relationship between FGF2 level and satellite cell health is non-monotonic (as also noted on dnam-muscle-function-markers). The satellite-cell-depletion mechanism may apply primarily at supra-physiological FGF2 levels in the aged niche rather than across the full range. gap/contradictory-evidence

Cross-references

fgf-signaling — the broader FGF ligand family and FGFR pathway; endocrine FGFs (FGF21, FGF23) are covered there; FGF2 is the paracrine muscle-niche member
satellite-cells — primary cell type regulated by FGF2 in aged muscle; niche signaling detail including FGF2/Notch/Wnt balance
skeletal-muscle — tissue context; sarcopenia mechanisms; FAP fate-shift
sarcopenia — downstream phenotype driven by satellite cell exhaustion via FGF2 niche disruption
stem-cell-exhaustion — hallmark that FGF2-driven satellite cell depletion exemplifies
altered-intercellular-communication — hallmark for FGF2 paracrine and SASP roles
chronic-inflammation — FGF2 as SASP component; NF-κB crosstalk
cellular-senescence — senescent cells secrete FGF2 as SASP; HMW isoform in stressed/senescent cells
ras-mapk — primary FGF2 downstream effector cascade
pi3k-akt-pathway — secondary downstream effector
dnam-muscle-function-markers — FGF2_30 blood methylation locus; correlates with sarcopenia severity; mechanistic discussion of FGF2 niche biology
spry1 — SPROUTY1, the FGF2-induced FGF signaling inhibitor that protects aged satellite cells from niche FGF2 excess (implicit stub)
fgfr1 — the primary FGF receptor mediating FGF2 effects in muscle/stem cells (implicit stub)
fgf21 — related endocrine FGF; metabolic regulator; distinct from FGF2 but related pathway (see fgf-signaling)

Footnotes

doi:10.1038/nature11438 · PMID 23023126 · PMC3605795 · Chakkalakal JV, Jones KM, Basson MA, Brack AS · Nature 2012;490(7420):355–360 · n=4–6 animals/group (immunohistochemistry); n=5 animals/group (single-fibre RT-qPCR); n=1,000 cells/condition (in vitro); in-vivo genetic manipulation of Spry1 and Fgfr1 in satellite cells via Pax7-CreER^TM^ · model: C57BL/6 mice; young ~2 mo vs aged ~24 mo · aged muscle fibre (not interstitial cells) is the principal source of Fgf2 under homeostatic conditions; Fgf2 niche signal drives satellite cell quiescence exit; Spry1 is selectively expressed in quiescent LRC satellite cells and suppressed by FGF2 signalling — its retention in LRCs maintains quiescence; Spry1 deletion from aged satellite cells worsened quiescence loss and reduced Pax7+ cells by ~50% vs aged controls; FGFR1 inhibition (SU5402) or Spry1 overexpression (SpryOX) prevented satellite cell depletion; verified against primary source PDF · 794 citations (OpenAlex) · green OA via PMC3605795 ↩ ↩² ↩³ ↩⁴
doi:10.1074/jbc.R115.689257 · PMID 26416892 · La Venuta G, Zeitler M, Steringer JP, Müller HM, Nickel W · J Biol Chem 2015;290(45):27015–27020 · mini-review · model: mammalian cell biology · describes FGF2 isoforms (18 kDa LMW secreted via ER/Golgi-independent route; 22–34 kDa HMW nuclear); unconventional secretion mechanism requiring PI(4,5)P2 and Tyr-215 phosphorylation; no signal peptide · closed-access; gap/no-fulltext-access — abstract-derived and review content ↩ ↩² ↩³
doi:10.1016/j.matbio.2016.07.007 · PMID 27496348 · Ghadiali RS, Guimond SE, Turnbull JE, Pisconti A · Matrix Biol 2017;59:54–68 · observational + in-vitro · model: mouse muscle cells; aging HSPG composition · dynamic changes in heparan sulfate sulfation patterns during muscle differentiation and aging alter myoblast fate and FGF2 signaling availability; aged HSPG composition shifts FGF2 presentation to satellite cells · closed-access; gap/no-fulltext-access — abstract-derived ↩ ↩²
doi:10.1016/j.imr.2016.05.001 · PMID 28462123 · Kim JS, Yoon DH, Kim HJ, Choi MJ, Song W · Integr Med Res 2016;5(3):230–235 · in-vivo · model: aged mice (resistance exercise intervention) · resistance exercise reduced FGF2 expression in skeletal muscle of aged mice; n and effect sizes not confirmed against full text · gap/no-fulltext-access — small animal study; human replication not performed; gap/needs-human-replication ↩
doi:10.1146/annurev-pathol-121808-102144 · PMID 20078217 · Coppé JP, Desprez PY, Krtolica A, Campisi J · Annu Rev Pathol 2010;5:99–118 · review · canonical SASP review; FGF2 (listed as “bFGF”) confirmed in Table 1 as a secreted growth factor upregulated in senescent human fibroblasts; verified against primary source PDF · green OA via doi ↩

🧬 Aging Wiki

Explorer

fgf2